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Cases ofAIDS in children under thirteen years ofage have been described since 1982.
Diagnosis is more difficult in children than in adults, owing to the more varied clinical
presentation and the difficulty in interpretation oflaboratory tests. Current diagnostic
criteria ofHIV infection are reviewed, as well as symptomatology, natural history, and
controversies surrounding management and therapy. Without afull appreciation ofthe
transmissibility ofHIV, issues including school and day-care attendance andfosterfamily
placement remain emotionally charged. Conflicting public policies contribute tofears on
the part ofthe general public. Because ofthe unique implicationsfor the entirefamily
when a child isfound to have HIV infection, the health care profession has been obliged to
confront complex psychosocial issues unparalleled in modern medicine. The medical
community mayprovide one safe environmentfor thefamily, and so the burden ofprovid-
ing supportfalls to a profession only variably trained and equippedfor this task. In the
absence ofa vaccine or a cure, public education directed atprimaryprevention and re-
duction ofstigmatization are the keys to true control ofthe epidemic.
The acquired immunodeficiency syndrome (AIDS) was first described in homosexual
males and intravenous drug users. It was recognized subsequently in recipients of
infected blood products and in heterosexual partners of infected individuals. More re-
cently, AIDS has been described in the population of infants born to infected mothers. In
1982, the first descriptions of this illness in children were reported. Retrospectively,
however, cases can be diagnosed since 1979 in this young population. The total number of
pediatric cases ofAIDS reported to the Centers for Disease Control (CDC) was 820 as of
February 8, 1988, but by 1991 this number is expected to reach over 3,000.'
The CDC has established strict criteria for the case definition of AIDS. Although these
criteria continue to be revised, it must be underscored that many cases of symptomatic
HIV infection may be excluded from the CDC count. Current studies of seroprevalence in
newborns indicate that in the inner city of Boston, 1 in 55 babies may be HIV-positive at
birth. 2 This approaches the highest rate of seroprevalence among newborns in New York
City. 3 Many, but not all, of these children will go on to develop symptomatology. The true
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impact of this statistic with respect to pediatric AIDS will be addressed later in this article.
Widespread recognition of pediatric AIDS as a specific disease entity was delayed for
several reasons. It was difficult to differentiate AIDS from other, already described
causes of congenital immunodeficiency syndromes. This differentiation required an elab-
orate combination of epidemiological observations, pathological studies, and specific
laboratory testing.
The clinical picture of AIDS in children remains quite distinct from that in adults. In
general, there is a greater heterogeneity in the clinical presentation of pediatric AIDS.
Although the well-known opportunistic infections seen in adult AIDS are also seen in
some pediatric cases, other infectious agents are common. In contrast to adult cases, the
types of pediatric infections first noted were bacterial, usually presenting as sepsis or
meningitis. Primary viral infections with herpes virus or cytomegalovirus were also docu-
mented, but it remained difficult to prove the causal association with the now well-known
retrovirus without more specific testing. Because of this and the relatively small number
of cases, it was difficult to establish epidemiological associations early in the epidemic.
There is also a greater severity of clinical disease in infants with AIDS, especially when
those without opportunistic infections are compared to adults. Death often occurs early,
sometimes before criteria are met to definitively establish the diagnosis of AIDS, thereby
further complicating epidemiological surveys and investigations. These factors undoubt-
edly contributed to difficulties in accepting early reports ofAIDS in infants, and continue
to cloud efforts to define AIDS in pediatric patients.
In order to help with the appropriate diagnosis of what was a newly described disease,
the Centers for Disease Control established specific case definition criteria for pediatric
AIDS in 1984. These criteria required modification a year later, as it became more and
more clear that the disease differed from AIDS in adults. In 1987, the CDC again revised
its definition. It developed a definition of AIDS in children under thirteen years of age, as
well as a classification schema for other forms of HIV infection in these children. The
system was designed to aid epidemiological studies, disease surveillance, prevention
programs, and health care planning and policy. So established, it is useful primarily in the
establishment of public health guidelines. It is less useful clinically, and individual pa-
tients must be considered separately with regard to management and prognosis.
Current Diagnosis
Ideally, HIV infection in children is identified by the actual presence of the virus in blood
or tissues. This may be confirmed by culture or antigen detection methods. Since these
techniques are not standardized tests as of yet, they are not readily available in most cen-
ters. In most areas, physicians must rely on the presence of antibody in the serum as evi-
dence of HIV exposure. This creates a particularly confusing situation when the infant is
born to an infected mother. It is currently believed that the maternal antibody passively
acquired by the infant from the mother while the infant is in utero may persist for up to
fifteen months. If the child demonstrates persistence of HIV antibody for longer than
fifteen months, he or she is considered to be truly infected, regardless of whether symp-
toms are present at that time. The problem arises in the child under fifteen months of age
who is seropositive. Seropositivity in the asymptomatic infant cannot be used to defini-
tively establish HIV infection. It is, however, an important marker, since it can certainly
identify the infant at highest risk. If actual virus cannot be demonstrated in the blood or
tissue by antigen or culture techniques, the child may be considered infected only if there
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is evidence of cellular and humoral immune deficiency as well as clinical symptomatol-
ogy. These symptoms may include progressive neurological disease, specified secondary
infectious diseases, secondary malignancies, or lymphoid interstitial pneumonitis. This
last entity is a histologically unique condition that causes a chronic and debilitating lung
disease in many children. As noted earlier, the definition of childhood AIDS remains
extremely restrictive as to the type and severity of symptoms; thus, there is an underre-
porting of this disease in the United States. The new classification schema, it is hoped,
will permit the identification of all children with AIDS as well as other forms of severe
HIV infection. It is also hoped that the new schema will ensure that all children with HIV
infection will be eligible for needed services and that these services will not be limited by
statutory or regulatory definitions of AIDS.
Natural History of Disease
The natural history of disease after HIV seroconversion in the pediatric age group is not
completely clear at this time.
The incubation period in the congenitally infected infant seems to be four to six months,
but it can be longer than five years in the transfusion-infected child. Most cases of pedi-
atric AIDS occur in very young children, with 50 percent of pediatric AIDS diagnosed
during the first year of life and 82 percent by the age of three years. 4
Although the clinical picture of congenital infection can and does vary significantly, a
profile has been suggested. Common features include failure to thrive, lymphadenopathy,
hepato-splenomegaly, chronic diarrhea, mucocutaneous candidiasis, and parotitis. Other
hallmarks are recurrent fevers and bacterial and viral infections as well as interstitial
pneumonitis. Children with lymphoid interstitial pneumonitis tend to become sympto-
matic later and have a better prognosis. Follow-up has not been extensive enough to pro-
vide true estimates of mortality, but CDC figures show that over 61 percent of children
reported with AIDS are known to have died. 5
Transmission
Since HIV infection in infants and children in this country is a relatively recent occur-
rence, a clear understanding of the modes of transmission is still evolving. It is well
known that in adults the major routes for HIV infection are close sexual contact, particu-
larly male homosexual contact; the sharing of needles and syringes in intravenous drug
users; and the receipt of blood or blood products.
In the older child, HIV can be associated with these same established routes of infec-
tion. The number ofAIDS patients identified during adolescence remains very low; this
may be explained by the long latency period of the virus. Behaviors commonly accepted
as high-risk may be initiated during these years, but symptoms of the disease may not
become evident until young adulthood. Adolescents should therefore be considered a
target population for education, counseling, and testing. Like adults, children have been
exposed to HIV during blood transfusions; these cases currently represent 13 percent of
all cases of AIDS in childhood. Another 5 percent of childhood AIDS cases can be attrib-
uted to blood products received as treatment for coagulation disorders. 6 There have also
been a few reports of HIV transmission to children occurring as the result of sexual abuse.
Most children with AIDS, however, are born to mothers who themselves carry the
virus. This perinatal exposure accounts for 80 percent of the children with AIDS. 7 Such
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mothers may have a history of intravenous drug use, prostitution, or multiple sexual part-
ners. They may practice no high-risk behaviors but simply originate from particular geo-
graphic regions where heterosexual transmission is thought to play a major role. Here in
New England we see a great number of patients from Haiti and central Africa, both of
which are considered endemic areas at this time. At the time of their pregnancy, these
mothers may be symptomatic, have AIDS or ARC, or be totally asymptomatic. Many are
unaware of their HIV antibody status, thus increasing the difficulty in recognition of
children at risk for congenitally acquired HIV infection.
The proof of transplacental transmission of HIV includes the suggestion by some inves-
tigators that HIV-infected infants have characteristic facial features. This would imply an
embryopathy secondary to fetal infection. This suggestion remains controversial, and
more children will need to be evaluated before it can be substantiated. The virus has been
isolated from the tissues of fetuses as well as from umbilical cord blood, and this stands to
indicate the presence of viral transmission from mother to infant. Transmission has been
documented in infants who have been born by Caesarean section and so have had no expo-
sure to vaginal secretions during the birthing process. In addition, infants have been found
to be seropositive, and later symptomatic, even in instances when there has been no post-
natal contact with the biological mother.
The incidence and the efficiency of HIV transmission in utero have not yet been well
defined. It does seem clear at this point, however, that transmission of the virus to the
fetus, while common, is not inevitable. With regard to twins, cases have been reported in
which only one infant was infected. By most conservative estimates, however, approxi-
mately 60 percent of infants born to mothers who are themselves seropositive are infected
with HIV. 8 There are no data to suggest that Caesarean section would lower the incidence
of HIV transmission from mothers to infants, but this is certainly a question that has been
raised in the medical community. Many studies are being conducted around the world in
order to obtain better answers to this very important question. In Boston alone, several
studies are trying to investigate the efficiency of transmission, the presence or possible
importance of other cofactors that may impact on that transmission, and the effect that
pregnancy itself may have on the progression of the disease in a seropositive woman.
Other types of perinatal transmission of HIV must be considered, although they proba-
bly do not play as major a role as transplacental passage of virus. These include passage
of the virus via infected breast milk. In support of this as a potential risk, there has been a
report of a child born by Caesarean section to a mother who received blood contaminated
with HIV after the delivery of the infant. This child seroconverted, with the only identifi-
able exposure being breast milk. 9
Although actual infective virus seems to be transmitted in approximately 60 percent of
cases, there is a passive transfer of maternal antibody in virtually 100 percent of infants
born to mothers who are themselves seropositive. This raises all sorts of social, political,
and medical dilemmas, since currently we are unable to identify those infants who are
most likely to become symptomatic. In those infants who are not truly infected, maternal
antibody seems to decrease over months, until finally the babies become seronegative.
Because this may take up to fifteen months, decisions regarding day care, immunizations,
and treatment modalities often become an issue before the question of true infectivity can
be resolved satisfactorily.
The actual incidence of HIV infection in infants will depend on several factors. These
include the number of children born to HIV-infected women as well as the prevalence of
seropositivity in the population of women who are of childbearing age. The prevalence of
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HIV has been clearly shown to be dependent on the subpopulation group and the geo-
graphic area studied. For example, 59 percent of intravenous drug users in New York City
are seropositive, while only 20 to 25 percent of intravenous drug users in Boston seem to
be seropositive. 10 In Worcester, this percentage was even lower but has recently been
found to be increasing rapidly." As the number of infected women continues to rise, we
can expect the incidence of HIV-infected infants to increase enormously.
The possibility of transmission of virus to family members and household contacts has
been a particularly sensitive issue. To date, in spite of exhaustive studies, there has been
no evidence to support the horizontal transmission of HIV with casual or usual household
contact. In one family study, a mother who cared for her transfusion-infected child did
seroconvert, but this was after very heavy and unusual exposure to blood, secretions, and
excreta without proper hand washing or the use of gloves. 12 In another study, a brother of
an HIV-infected child did become seropositive. 13 The only unusual exposure that was
documented was a bite from the infected child. The causal relationship has not been posi-
tively determined in this case. Although HIV has been cultured from both tears and sa-
liva, these are considered to be fluids with a very low titer of virus, and to date there have
been no reports of transmission via exposure to these secretions.
A question has been raised as to the susceptibility of the infant and the young child to
HIV. Although more investigation is needed before a clear understanding can be acquired,
it seems that increased susceptibility may indeed be a factor, as evidenced by several epi-
demiological studies. In a study of transfusion-related AIDS, infants accounted for 10
percent of cases even though they had received only 2 percent of the total number of blood
transfusions. There also seemed to be a shorter latency period between exposure to virus
and onset of symptoms. This may be attributed to the relative size of transfusion, and
therefore the load of virus.
Controversial Management Modalities
The mainstay of the management of the child with HIV infection has been largely a sup-
portive one. Prompt recognition and treatment of all infections are of the utmost impor-
tance, as is the maintenance of good nutritional status. However, a few issues have
prompted debate among the health care professionals who are caring for these children.
The utilization of immunizations has been controversial in the population of children
infected with HIV. The potential hazards of the vaccines themselves must be weighed
against the risk from the diseases they are designed to prevent. It has been suggested that
the stimulation from the vaccine itself may cause a deterioration in the clinical status of an
infected child.
The risk of live virus vaccines such as MMR (measles/mumps/rubella) and oral polio
vaccine has been specifically debated. In general, children who are immunocompromised
by other deficiencies or by chemotherapeutic ablation are at risk for acquiring the disease
from a vaccine of this type. These vaccines are therefore not recommended for this popu-
lation. With regard to HIV-infected children specifically, several retrospective studies
have investigated the outcome when seropositive children were inadvertently given oral
polio vaccine. Because no ill effects have been reported, and because not all seropositive
infants are truly HIV-infected, current recommendations from the CDC suggest that if the
child is asymptomatic it may be safe to administer routine immunization. Specific recom-
mendations of the national Immunization Practices Advisory Committee in regard to the
immunization of HIV-seropositive children have been published, but differences of opin-
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ion still exist. 14 Some feel that the theoretical risk is quite substantial and that until a large
number of children have been studied, it may be wise to be conservative. At Boston City
Hospital, we recommend the use of inactivated polio vaccine in all seropositive children,
whether symptomatic or not. We feel more comfortable with this practice not only with
respect to the infant's safety, but also because these children often have infected care-
takers. Polio virus is shed in the stool for weeks to months after oral vaccine is given, and
this would put infected guardians at some risk as well. We remain consistent in our view
of the risk associated with live virus vaccine and thus withhold measles/mumps/rubella
immunizations from seropositive children as well, although this represents no risk to
other family contacts.
Inactivated polio vaccine is often difficult to obtain; when it is available, it is more
costly than oral, live vaccine. In areas where immunization practices are being debated,
the theoretical risk of the oral vaccine must be weighed against the relative accessibility of
the inactivated form. Other routine vaccinations of childhood should be given, although
some data suggest that the vaccine may not result in the production of functional antibody.
When exposure to chicken pox occurs, these children should also be given passive immu-
nization, although efficacy has not yet been determined.
The biggest problem in the management of the child with HIV infection is control of the
recurrent infections that may progress to sepsis, pneumonia, and meningitis. Optimal
strategies to prevent this have not yet been established. Many centers have recommended
the use of prophylactic antibiotics, but these carry with them the risk of side effects, poor
compliance, and the emergence of resistant bacterial strains.
Given the predisposition of children with HIV infection to develop recurrent bacterial
infections, the use of prophylactic intravenous immunoglobulin (TVIG) has been sug-
gested. A few studies have been reported, but no firm data that are based on controlled
clinical trials are available. Because of a lack of other effective therapies, these early,
subjective reports resulted in fairly widespread use of this preparation. Now, with the
number of HIV-infected children climbing rapidly and the average cost per child of
monthly IVIG totaling approximately $30,000 per year, there is pressure to demonstrate
efficacy. In addition, some feel that monthly visits to the hospital for intravenous therapy
may represent undue exposure to other infectious agents. Currently, a multicenter study
funded by the National Institutes of Health is executing a double-blind placebo-controlled
trial to address this issue rapidly and accurately. The Boston University School of Medi-
cine is actively participating in this trial.
Special Antiviral Therapies: Choices and Dilemmas
The devastating and frequently occurring central nervous system disease in children with
HIV infection has to be taken into consideration when a specific antiviral agent is chosen
for study. Any antiviral drug that does not penetrate the blood brain barrier may be of
little benefit in the pediatric age group.
As new antiviral agents become available for study in children with HIV infection, it
will be important to have modes of comparison already established. In this way, all chil-
dren will be able to receive therapy already proven to have some efficacy, either in control
of symptoms or in activity against the retrovirus. The ultimate goal of therapy for HIV
infection would be to control or ablate the infection altogether, and also restore the indi-
vidual's ability to reconstitute normal immune function.
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Although there are many potential targets for antiviral drugs, most recent efforts have
been aimed at inhibiting the DNA polymerase that is unique to the retrovirus. Of the
candidate antiviral agents for testing in children, the most publicized has been Azidothy-
midine (AZT). Preliminary trials have already begun in several centers so that optimal
dosage regimens can be established. Although AZT has been shown to be efficacious in
adults with AIDS and has been licensed for clinical use, it is not without problems. It is
quite toxic, and most patients taking it have developed anemia severe enough to necessi-
tate blood transfusion. Other cell lines of the bone marrow may also be affected. In addi-
tion, there may be other side effects, such as nausea, vomiting, and central nervous
system disturbances. Although HIV antigen has been demonstrated to decrease during
AZT therapy, it returns with cessation of treatment. AZT must therefore be considered
lifelong therapy. It is not known how children will respond to this drug.
Severe opportunistic infections with viral, bacterial, and parasitic pathogens have
spawned active research in the area of new therapies for these specific pathogens as well.
New drugs have been developed and tested for cytomegalovirus, herpes, and Pneumocys-
tis carinii infections. While these therapies may have no effect on HIV per se, they have
had a great impact on the care of the infected patient.
Many AIDS patients, both adult and children, have received new therapies of one sort
or another on experimental protocols after informed consent has been obtained. This has
created a legal dilemma, especially in regard to the pediatric patient. Many of these chil-
dren are in foster care families, with legal custody being in the hands of the state social
services department. This brings up many legal questions of risk and liability on the
part of the governmental agency that grants permission for participation in experimental
protocols.
Of course, this problem is unique to pediatrics, since the patient is a minor and is there-
fore unable to give informed consent on his or her own behalf. Traditionally, it has been
difficult to obtain permission in circumstances such as these. However, as more and more
protocols become available, and as the number of children with devastating disease in-
creases, these "experimental" therapies will become standard of care. The legal ques-
tions regarding liability will need to be weighed against the ethical issue of withholding
possible effective therapy from children with otherwise fatal disease.
Public Health and Policy Issues
Education and day care of children with HIV infection is an emotionally charged topic,
because of the severity of disease and the fear on the part of the general public. Pressure
on those who make public policy has prompted hasty and sometimes overly conservative
decisions. It is important to underscore again that there has been no documentation of
HIV transmission in the school, at day care, or in any other casual setting.
Current guidelines from the Centers for Disease Control confirm that school-age chil-
dren who have evidence of HIV infection can be comfortably included in the classroom
setting. Certain unusual circumstances, however, do require special consideration in this
regard. For example, children who have oozing lesions or recurrent bleeding or who lack
control of their bodily secretions may pose a greater risk to their classmates. Moreover,
children who may not be developmentally appropriate and who may therefore exhibit
abnormal behavior, such as excessive biting, may need to be excluded from the general
classroom. Although it is still unclear whether even these children truly represent a sig-
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nificant risk to their classmates, the Massachusetts Governor's Task Force on AIDS has
upheld the CDC guidelines.
Currently, the true responsibility for creating guidelines to deal with this sensitive issue
falls to local authorities. The guidelines are much more restrictive in some states than in
others. Still other states have avoided the issue when possible. These discrepancies further
fuel apprehensive parent and political groups, by underscoring the uncertainty on the part
of policymakers as to the real danger that might exist. The Report ofthe Surgeon Gen-
eral's Workshop on Children with HIV Infection and Their Families, published in July
1987, suggests that the decision about whether to attend school is best left to the individ-
ual's physician. 15 This decision should be based on the general health of the individual and
on a judgment as to whether school attendance would indeed pose a risk to the patient by
way of excessive exposure to infectious agents. The report states that under ideal circum-
stances, an individual at the school should be aware of the diagnosis; however, the need
for confidentiality gives children the right to have the information withheld from the
school. The report emphasizes that realistic guidelines based on best current knowledge
should be considered by school boards, principals, and physicians. Resources should be
developed for dissemination and implementation of new information as it becomes availa-
ble. The report also deals with the issue of day care for the preschooler or the develop-
mentally delayed older child. It suggests that these toddlers be allowed to attend day care
unless scientific evidence suggests that exposure of this sort could place at risk the other,
uninfected children. So far, investigators have been unable to collect this evidence, and for
this reason these children should not be excluded from day care arrangements.
In Massachusetts, conservative guidelines exclude children under three years of age
with evidence of HIV infection from attending a group day care setting. This raises issues
of ethical, political, and economic importance. While health care workers try to encour-
age HIV testing in high-risk populations, the day care guideline represents yet another
negative incentive to families. With no alternative to day care, one or both parents may be
forced out of the workplace to stay at home with the child. Coupled with the fact that one
adult may be symptomatic from HIV infection, this adds yet another burden to an already
stressful situation. Because the guidelines pertain to those infants who merely have evi-
dence of maternal antibody (since it may not be possible to distinguish these children from
those with true infection), the problem is aggravated still further. Counselors and health
care workers are often faced with a difficult dilemma. Reporting to day care organizers
may represent a breach of confidentiality, and so infringements of state regulations may
go uncorrected anyway. The question of legal obligation in these circumstances is a most
difficult one, and ultimately may have to be resolved by the judicial system.
Another area where lack of federal guidelines has forced local authorities to make diffi-
cult decisions is foster care. Because legal custody is in the hands of a government agency
when a child is placed in foster care, the question of informed consent for HIV testing is a
sensitive one. Physicians can obtain approval for testing from most social service agen-
cies, but confidentiality guidelines vary. In some cases, foster families are not informed of
the test results. This raises obvious questions of liability, since precautions for family
members and medical care for the child in question may not be adequately addressed.
Psychosocial Issues and Counseling
Aside from all of the new and unusual questions that have been raised with regard to HIV,
the psychosocial issues have created new challenges to the health care system. The stigma-
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tization of this disease has complicated the health and social care of the infected individ-
uals. School-age children have become the focus of teachers', other pupils', and neighbors'
fears. Ostracism and resultant low self-esteem have often been the outcome of this public
frenzy and fear. Adolescents who have acquired this disease by engaging in "high-risk
behaviors" must deal with admissions to the behaviors in addition to the disease itself.
Well-publicized incidents of discrimination, accompanied at times by acts of violence,
have created an environment in which the family with an infected individual has some-
times chosen to be totally anonymous rather than search for help. This reduces the possi-
bility of psychiatric, social service, religious, or community support.
In addition, the misconceptions within different cultural, ethnic, and even community
groups have further complicated the feeling of alienation on the part of the afflicted fam-
ily. Some individuals have been forced out of housing, others turned away by their family
or friends. In some cases, churches have been afraid to give comfort to these families,
even refusing to house funeral or memorial services. In addition to the obvious psychoso-
cial burden on the family, this places a great stress and responsibility on the medical com-
munity, since it is often only through this system that any support may be obtained. This is
considered a "safer" environment in which to vent frustrations, anger, and sadness sur-
rounding the diagnosis; but it means that the medical staff often accepts this burden alone.
Identification of a seropositive infant brings up other problems for the family. Many of
these children are already the victims of drug-using families and low socioeconomic sta-
tus. When a mother is told that her infant is seropositive, she must also be told of the like-
lihood that she herself is infected with HIV. This message must convey the serious and
usually fatal nature of the illness in the infant; the likelihood of infection and potential for
illness and death in the parents; the need for changes in sexual expression in order to
prevent subsequent transmission; and the possibility of avoidance of future pregnancies.
Fear, guilt, and sadness further complicate an already complicated scenario. An older,
uninfected sibling must face the possibility of losing not only a sibling, but both parents as
well. This type of "family disease" has not been described or paralleled in modern medi-
cine.
Any discussion of the psychosocial issues regarding HIV infection must include the
medical team and other support services through which care is provided for the child.
Because of the problems just discussed, caring for these patients can be a draining experi-
ence for the pediatricians, who usually see patients improve under their care. Even for
physicians and others who care for chronically and terminally ill children, the family
nature of this disease can be overwhelming. The social problems are far-reaching, and the
feeling of impotence on the part of the medical team can reach a point of desperation. A
large number of people are needed to care for a particular child, owing to the multidisci-
plinary nature of the required services, and this can lead to miscommunications. We have
found that regularly scheduled discussion and support groups are necessary for dealing
with this situation, especially as a particular child becomes more symptomatic and hospi-
talizations become more frequent and prolonged. As the number of infected children
increases, we will have to look to other techniques to reduce burnout and depression
among health care workers.
A Comprehensive Approach to the Problem
Owing to the unique problems presented to the medical community by the child with HIV
infection, new approaches to the organization and execution of care have been attempted.
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The Boston Comprehensive Pediatrics AIDS Program is the residential unit for infants
and toddlers with HIV infection who cannot be cared for at home. The program functions
within the Boston City Hospital grounds, with support from the Massachusetts Depart-
ment of Public Health and the Boston Department of Health and Hospitals. It is set up as a
home for these children until their parents are able to care for them or until other parent-
ing arrangements can be made. It currently has a four-bed capacity, and, almost since the
program opened in February 1987, there has been a waiting list for these beds. Respite
workers provide direct child care on a twenty-four-hour basis. The philosophy of the
program supports and facilitates the creation of a warm, caring environment. Through the
combined efforts of a program coordinator, a social worker, a registered nurse, eight
child health care workers, and volunteers, this program offers each child a specialized
program for promoting maximum wellness. When it is appropriate, families are included
in activities. Overnight visits, which allow the parents to learn to care for their child's
special needs, may facilitate preparations for eventual discharge. This residential unit was
developed for children who are medically stable and who need only "home medical care."
When a child has an acute problem for which she or he needs ongoing medical care, trans-
fer to an inpatient ward is arranged. This separation allows for a normalization of life for
children while they are in the residential facility.
Also at Boston City Hospital is housed Boston's only outpatient medical clinic designed
to deliver multidisciplinary care to pediatric patients with HIV infection. Care is provided
through a team approach, and staffing consists of infectious disease specialists as well as
other subspecialty physicians. All children are followed with nutritional and developmen-
tal assessments. Social service and educational counseling are available to all patients as
well. Communication with primary care physicians who have referred patients is main-
tained, and the program works in close association with the Boston City Hospital Adult
AIDS Program, further establishing a family-based treatment program. The same team
follows the patient and helps direct decision making when the child is admitted to the
hospital, thus providing care of these families. In addition, all appropriate treatment pro-
tocols are made available to these patients and their families.
Control of the Epidemic
Currently, very exhaustive attempts are being made to develop a vaccine that will prevent
HIV infection in individuals who have not yet been exposed. Numerous problems exist,
making the search for an effective vaccine a very difficult one. The effort is complicated
by the diversity of subtypes of the virus and by the lack of knowledge regarding the actual
role of antibodies and cell-mediated immunity in the defense against HIV.
The objective of most investigators working on candidate vaccines is to develop a vac-
cine that will induce neutralizing antibody. It has been shown, however, that most patients
with HIV infection have neutralizing antibody that is not effective in preventing AIDS.
Direct cell-to-cell spread of virus may exist in conjunction with virus latency to "protect"
HIV from the immune system. At the present time, it is not known how vaccination will
effect either seronegative or seropositive donors. Animal testing is hampered by a short-
age of chimpanzees; therefore, it will probably be necessary to test most vaccines in HIV-
seronegative human volunteers.
We are a long way from being able to rely on a vaccine to control this epidemic, so
other avenues must be explored.
Although universal blood screening of blood and blood products for HIV has not elimi-
130
nated the risk of transfusion-associated acquisition of HIV, it was an important step in
decreasing the number of new cases. Because of the long latency period of the virus, how-
ever, new transfusion-related cases will continue to be diagnosed for some time.
Prevention of perinatally acquired disease will depend on the number of births to HIV-
infected women. Efforts to identify and educate infected women who can transmit HIV to
their children must be aggressive. Women who are at high risk must be counseled to un-
dergo voluntary screening, and they must be educated about the risks associated with
pregnancy in the seropositive mother. Of course, education must also focus on behavioral
modification, including avoidance of high-risk sexual activities and of intravenous drug
use.
Clearly, populations that are already at high risk must be counseled and educated. But
the true spread of the AIDS epidemic will not be controlled until the general public is
made aware of the risks. Containment of this disease will rest on our ability to effect
changes in behavior and lifestyle so that the chain of transmission can be broken. The
mass media, which often emphasize the sensational aspects of the AIDS epidemic, must
educate the public so that fear does not spawn drastic policy measures that are unwar-
ranted in terms of what is known about the actual risk.
Significant portions of the population, including intravenous drug users, adolescents,
and persons with language barriers, are not being reached with the educational message
conveyed through traditional media. The techniques of marketing research should be used
to identify the most effective means of communicating with all segments of the popula-
tion. Alternative communication resources should be explored. Only in this way can the
stigmatization be reduced, thus allowing affected individuals to openly be counseled,
tested, and provided with care. Without these measures, the number of HIV-infected
adults, children, and infants will continue to grow to even more tragic proportions. ^
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Glossary
ADCC.
Adjuvants.
Cytotoxic (killer) T-cells.
Lymphokines.
Transmucosally.
Virion.
Antibody-dependent cell-mediated cytotoxicity.
Materials used with vaccines to enhance the activity of a
vaccine.
A component of the immune response involving a subgroup
of lymphocytes that kill virus-infected cells.
Chemicals produced by lymphocytes to communicate with
other lymphocytes.
Across mucous membranes such as those lining the vagina
and rectum.
A single virus particle.
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